<DOC>
	<DOCNO>NCT01058759</DOCNO>
	<brief_summary>Taxotere-Enoxaparin- ( ENOXA ) -Study : 1st-Line Docetaxel-Platin Chemotherapy single therapy combination Enoxaparin patient age old 18 year locally advance metastatic non-small cell lung cancer ( stadium IIIb/IV ) , phase III study . Study hypothesis : Increase progressive free survival 5 7.5 month .</brief_summary>
	<brief_title>Taxotere-Enoxaparin- ( ENOXA ) -Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Signed informed consent Men woman age 18 old Locally Advanced Metastatic Nonsmall Cell Lung Cancer stage IIIB/IV without previous therapy Life expectancy least 12 week EOCG performance &lt; 1 Appropriate renal hepatic function Appropriate Hematology No bleed event within 4 week prior randomization No indication prophylactic therapeutic anticoagulation therapy Appropriate method contraception ( : men woman ) woman childbearing potential negative urine pregnancy test within 7 day prior randomization Capability s.c. injection Enoxaparin every 24 hrs History cancer NSCLC Known contraindication Enoxaparin e.g . HIT , Known contraindication Docetaxel , Cisplatin , Carboplatin comedication Participation clinical trial within 30 day prior randomization Any known medical condition allow therapy accord study protocol Seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Enoxaparin</keyword>
	<keyword>Locally Advanced Metastatic Non-small Cell Lung Cancer stadium IIIb/IV</keyword>
</DOC>